Rapid7 (RPD) PT Raised to $40 at Susquehanna

Go back to Rapid7 (RPD) PT Raised to $40 at Susquehanna

Rapid7 (RPD) PT Raised to $40 at RBC Capital

August 7, 2018 8:08 AM EDT

RBC Capital raised its price target on Rapid7 (NASDAQ: RPD) to $40.00 (from $38.00) while maintaining an Outperform rating following results.

Analyst Matthew Hedberg said momentum continues to build as Rapid7 steadily executes and even accelerates the recurring revenue transition.

... More

Rapid7 (RPD) PT Raised to $42 at Stifel

August 7, 2018 7:36 AM EDT

Stifel raised its price target on Rapid7 (NASDAQ: RPD) to $42.00 (from $36.00) while maintaining a Buy rating.

... More

Rapid7 (RPD) PT Raised to $32 at Morgan Stanley

August 7, 2018 7:13 AM EDT

Morgan Stanley raised its price target on Rapid7 (NASDAQ: RPD) to $32.00 (from $30.00) while maintaining a Equalweight rating.

... More

Rapid7 (RPD) PT Raised to $38 at KeyBanc

August 7, 2018 4:09 AM EDT

KeyBanc raised its price target on Rapid7 (NASDAQ: RPD) to $38.00 (from $35.00) while maintaining a Overweight rating.

... More

Rapid7 (RPD) PT Raised to $37 at Barclays

August 7, 2018 3:56 AM EDT

Barclays raised its price target on Rapid7 (NASDAQ: RPD) to $37.00 (from $36.00) while maintaining a Overweight rating.

... More

After-Hours Stock Movers 08/06: (VCEL) (TWLO) (ALSK) Higher; (GEMP) (ZG) (MXWL) Lower (more...)

August 6, 2018 6:10 PM EDT

Today's After-Hours Movers

Gemphire Therapeutics Inc. (NASDAQ: GEMP) 21.7% LOWER; announced that the U.S. Food and Drug Administration (FDA) has requested that the Company produce data from a sub-chronic toxicology study to provide information to support lifting the partial clinical hold on gemcabene with respect to clinical trials of longer than six months in duration. The FDA also informed the Company that the End of Phase 2 meeting, and consequently the initiation of Phase 3 trials investigating gemcabene in dyslipidemia indications and long-term safety exposure trials needed for registration,... More

Rapid7, Inc. (RPD) Tops Q2 EPS by 6c, Revenues Beat; Offers FY18 EPS/Revenue Outlook

August 6, 2018 4:13 PM EDT

Rapid7, Inc. (NASDAQ: RPD) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $58.4 million versus the consensus estimate of $55.14 million.

Rapid7 had a great second quarter, with strong performance around the world and across our solutions, said Corey Thomas, President and CEO of Rapid7. For the fourth quarter in a row, ARR growth accelerated, reaching 44%, driven by new customer growth, upsells and cross-sells, and the success of our shift... More